Related references
Note: Only part of the references are listed.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma
Wen Sun et al.
CLINICAL CANCER RESEARCH (2020)
Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations
Audrey Debaillon Vesque et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2020)
Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma
David J. Pinato et al.
BRITISH JOURNAL OF CANCER (2019)
Aurora-a confers radioresistance in human hepatocellular carcinoma by activating NF-κB signaling pathway
Ze-Tian Shen et al.
BMC CANCER (2019)
Role of the receptor tyrosine kinase Axl in hepatocellular carcinoma and its clinical relevance
Zhao-Shan Niu et al.
FUTURE ONCOLOGY (2019)
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver et al.
LEUKEMIA (2019)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies
Marie Schoumacher et al.
CURRENT ONCOLOGY REPORTS (2017)
Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma
Fuchen Liu et al.
ONCOTARGET (2017)
Medical Management of Hepatocellular Carcinoma
Nicole E. Rich et al.
JOURNAL OF ONCOLOGY PRACTICE (2017)
Drug-biomarker co-development in oncology-20 years and counting
Julianne D. Twomey et al.
DRUG RESISTANCE UPDATES (2017)
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
L. Zhou et al.
ONCOGENE (2016)
Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells
Zeynep Firtina Karagonlar et al.
CANCER SCIENCE (2016)
A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer
Daniel Dauch et al.
NATURE MEDICINE (2016)
Role of FLT3 in the proliferation and aggressiveness of hepatocellular carcinoma
Muammer Merve Aydin et al.
TURKISH JOURNAL OF MEDICAL SCIENCES (2016)
Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation
Yung Chang Hsu et al.
ONCOTARGET (2016)
Axl Expression Stratifies Patients with Poor Prognosis after Hepatectomy for Hepatocellular Carcinoma
Jian Liu et al.
PLOS ONE (2016)
Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research
Bin Chen et al.
BMC MEDICAL GENOMICS (2015)
Aurora Kinase inhibitors: Current Status and Outlook
Vassilios Bavetsias et al.
FRONTIERS IN ONCOLOGY (2015)
HTSeq-a Python framework to work with high-throughput sequencing data
Simon Anders et al.
BIOINFORMATICS (2015)
Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges
Gan-Lu Deng et al.
WORLD JOURNAL OF HEPATOLOGY (2015)
STAT3 Mediates Regorafenib-Induced Apoptosis in Hepatocellular Carcinoma
Wei-Tien Tai et al.
CLINICAL CANCER RESEARCH (2014)
Inhibition of Aurora-B suppresses HepG2 cell invasion and migration via the PI3K/Akt/NF-κB signaling pathway in vitro
Ren Feng Shan et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2014)
Aurora-A promotes chemoresistance in hepatocelluar carcinoma by targeting NF-kappaB/microRNA-21/PTEN signaling pathway
Kai Zhang et al.
ONCOTARGET (2014)
The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer
Douglas K. Graham et al.
NATURE REVIEWS CANCER (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions
Daehwan Kim et al.
GENOME BIOLOGY (2013)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC
Zhong-Zhe Lin et al.
BMC CANCER (2010)
The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma
Arihiro Aihara et al.
JOURNAL OF HEPATOLOGY (2010)
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
S. Whittaker et al.
ONCOGENE (2010)
The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma
Zhong-Zhe Lin et al.
JOURNAL OF HEPATOLOGY (2009)
Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells
Phillip Kaestner et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome
Ben Langmead et al.
GENOME BIOLOGY (2009)
Aurora Kinase Inhibitor PHA-739358 Suppresses Growth of Hepatocellular Carcinoma In Vitro and in a Xenograft Mouse Model
Daniel Benten et al.
NEOPLASIA (2009)
Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocelluar carcinoma after curative hepatectomy
S. Tanaka et al.
BRITISH JOURNAL OF SURGERY (2008)
Cloning and expression profile of FLT3 gene during progenitor cell-dependent liver regeneration
Iraz T. Aydin et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2007)
Aurora kinases, aneuploidy and cancer, a coincidence or a real link?
R Giet et al.
TRENDS IN CELL BIOLOGY (2005)
Overexpression and amplification of Aurora-A in hepatocellular carcinoma
YM Jeng et al.
CLINICAL CANCER RESEARCH (2004)
The cellular geography of aurora kinases
M Carmena et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Mouse A6-positive hepatic oval cells also express several hematopoietic stem cell markers
BE Petersen et al.
HEPATOLOGY (2003)
Share Paper
